| AGM Gives Another Confident Update | Equity Development

Wed 11:33am by Equity Development

0 comments 67 reads

In a statement to accompany today’s AGM, Cohort reported that, propelled by trading and order intake, notably in the Sensors & Effectors division, H1 25 is expected to be significantly ahead year-on-year, with net margin improvement. The Group indicates that FY25 revenue and (adj.) operating profit are now expected to be slightly ahead of management prior expectations.

The year-end record closing order book was £518.7m, with visibility out to 2037 and an estimated 90% of FY25 consensus estimated revenue covered. Post FY24 results the Group has continued to add contract wins worth over £120m taking the total to £575m by 20 September.

We have revised our FY25 revenue estimate up by 4.5%, from £220m to £230m, also raising (adj.) EBIT by 2.2% to £24.6m (prior £24.0m). Cohort currently trades on 9.6x FY26E (adj.) EV/EBITDA, 17.6x PE compared to the market cap weighted average of peers on respective multiples of 12.1x and 21.1x

At this stage, our Fair Value remains 910p / share and the link to our research report is here: https://www.equitydevelopment....

Unlock with Email

Unlock with Google

Already have an account?
Login here

About the Author

Equity Development

Premium Member

Equity Development Limited is regulated by the Financial Conduct Authority Disclaimer Equity Development Limited (‘ED’) is retained to act as financial adviser for its corporate clients, some or all of whom may now or in the future have an interest in the contents of this document. ED produces and distributes research for these corporate clients to persons who are not clients of ED. In the preparation of this report ED has taken professional efforts to ensure that the facts stated herein are clear, fair and not misleading, but makes no guarantee as to the accuracy or completeness of the information or opinions contained herein. This document has not been approved for the purposes of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom (‘FSMA’). Any reader of this research should not act or rely on this document or any of its contents. This report is being provided by ED to provide background information about the subject of the research to relevant persons, as defined by the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. Research produced and distributed by ED on its client companies is normally commissioned and paid for by those companies themselves (‘issuer financed research’) and as such is not deemed to be independent as defined by the FCA but is ‘objective’ in that the authors are stating their own opinions. This document is prepared for clients under UK law. In the UK, companies quoted on AIM are subject to lighter due diligence than shares quoted on the main market and are therefore more likely to carry a higher degree of risk than main market companies. ED may in the future provide, or may have in the past provided, investment banking services to the subject of this report. ED, its Directors or persons connected may at some time in the future have, or have had in the past, a material investment in the Company. ED, its affiliates, officers, directors and employees, will not be liable for any loss or damage arising from any use of this document to the maximum extent that the law permits. More information is available on our website www.equitydevelopment.co.uk more »

0 comments

Be the first to comment by using the form above.

>

Unlock the metrics for all these stocks and more...

Take a free trial

© Stockopedia 2024, Refinitiv, Share Data Services.

Facebook Twitter Youtube Instagram RSS

This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.

Unlock the metrics for all these stocks and more...

Take a free trial